A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

Inclusion Criteria:

* Ability to understand and willingness to sign a written Informed Consent
* Advanced relapsed or refractory predominantly non squamous NSCLC. The diagnosis must have been confirmed cyto-/ histologically
* Patients must have measurable or non-measurable disease
* At least two but not more than three prior standard treatment regimens for NSCLC
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
* Male or female subjects \>/= 18 years of age (\>/=20 for Japan) at the time of Informed Consent
* Life expectancy of at least 12 weeks
* Ability to swallow oral medication
* Both men and women using adequate barrier birth control measures during the course of the trial and 4 weeks after the completion of trial
* Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of the study drug:

  * Haemoglobin \> 9.0 g/dl
  * Absolute neutrophil count (ANC) \>1,500/mm3
  * Platelet count \>/= 100,000/µl
  * Total bilirubin \</=1.5 x the upper limit of normal
  * Alanine aminotransferase (ALT) \< 2.5 x upper limit of normal (\</= 5 x upper limit of normal in patients with liver metastases) Aspartate aminotransferase (AST) \< 2.5 x upper limit of normal (\</= 5 x upper limit of normal in patients with liver metastases)
  * Alkaline phosphatase \< 4 x upper limit of normal (\</= 5 x upper limit of normal in patients with liver metastases)
  * Prothrombin Time (PT)-International Normalized Ratio (INR) or Partial Thromboplastin Time (PTT) \< 1.5 x upper limit of normal
  * Serum creatinine \< 1.5 x upper limit of normal
  * Calculated creatinine clearance of \>/= 50 mL/min

Exclusion Criteria:

* NSCLC patients with predominantly squamous cell carcinoma histology

Excluded medical conditions:

* History of cardiac disease: Congestive heart failure, Active coronary artery disease (CAD), Cardiac arrhythmias (\>Grade 2 NCI-CTCAE \[National Cancer Institute-Common Terminology Criteria for Adverse Events\] vers. 3.0)
* Uncontrolled hypertension despite two anti-hypertensive medications
* History of Human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
* History of organ allograft
* Active clinically serious infections (\> grade 2 NCI-CTCAE vers. 3.0)
* Patients with seizure disorder requiring medication
* Patients with evidence or history of bleeding diathesis or coagulopathy
* Patients undergoing renal dialysis
* Pulmonary hemorrhage/ bleeding event \>/= CTCAE grade 2 within four weeks prior to the first dose of the study drug
* Any other hemorrhage/ bleeding event \>/= CTCAE grade 3 within four weeks prior to the first dose of the study drug
* Thrombotic or embolic venous or arterial events such as cerebrovascular accident
* Pregnant or breast-feeding women.
* Any condition which could affect the absorption or pharmacokinetics of the study drug
* Prior treatment with other Vascular Endothelial Growth Factor (VEGF) (R) inhibitors, including compounds that impact vascularity (i.e. sunitinib, thalidomide, vandetanib, vascular disrupting agents \[VDA\], VEGF-trap and other experimental agents of this class). Only bevacizumab (Avastin) is permitted.